At just after 5 am on 11 December 2025, the EU Parliament and the Council reached agreement on a new directive and a new regulation that will result in a major update to the EU’s pharmaceutical laws. Progress towards these new rules began in 2016 and are the result of over two years of negotiations
Latest Post
More Posts
The Covington European Life Sciences Symposium 2025
EMA Clinical Data Publication Policy to Cover All New Marketing Authorization Applications, Line Extensions and Major Clinical Type II Variations Starting Q2 2025
New ABPI Code and PMCPA Constitution and Procedure Published
European Parliament adopts its Position on EU Pharma Law Review: 8 Key Takeaways for Industry
UK HRA Consults on a New Model Investigator-Initiated Study Agreement
Consultation on Changes to the ABPI Code and UK Advertising Complaints Process
UK Government Consults on Proposals Mandating the Disclosure of Industry Payments to the Healthcare Sector
EU Talking Life Sciences Audiocast: Clinical Trial Transparency Requirements in the EU
Update on the VPAS Judicial Review brought by the British Generic Manufacturers Association
Connect: http://www.cov.com/rblaney/
Subscribe: Subscribe via RSS